KalVista Pharmaceuticals Announces Positive Phase 1 Data for Orally Disintegrating Tablet Formulation of Sebetralstat for Use in Hereditary Angioedema

CAMBRIDGE, Mass. & SALISBURY, England–(BUSINESS WIRE)—- $KALV–KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced positive phase 1 data for an orally disintegrating tablet (ODT) formulation for its lead compound sebetralstat. Sebetralstat is currently being developed in the phase 3 KONFIDENT clinical trial as a potential on-demand treatment for h
Click here to view original post